ASH 2020 | CLL highlights at ASH 2020
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, outlines the key advances in chronic lymphocytic leukemia (CLL) presented at ASH 2020. Dr Al-Sawaf discusses the promising results seen with fixed-duration, targeted combination approaches, such as the ibrutinib plus venetoclax regimen currently being researched in the Phase II CAPTIVATE trial (NCT02910583) and in the CLARITY study (ISCRTN13751862). Dr Al-Sawaf highlights that these approaches are still not mature, with long-term follow-ups still required. Furthermore, Dr Al-Sawaf discusses advances in achieving low measurable residual disease (MRD) in both front-line and relapsed/refractory settings. Emerging data on cellular immunotherapy in CLL suggests durable clinical responses in patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
